Pharma Q2 Preview - Domestic Formulations Normalising; Continued Headwinds In U.S. Generics: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
From the peak YoY earnings growth of 48% achieved in Q3 FY21, YoY earnings growth has been on the downtrend on an aggregate basis for companies under our coverage.
We expect earnings to be flat YoY in Q2 FY22 on an aggregate basis.
Increased competitive pressure on the U.S. base business – coupled with the reduced pace of launches and lower Covid-19 related off-take is expected to drag the overall performance of the sector for the quarter.
Supply chain disruption continues to take a toll on company margins due to increased raw material costs and limited scope to pass this on to customers.
Improved doctor-patient connect in domestic formulation and the revival of non-Covid-19 medicine are expected to offset the drag, to some extent.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.